PROGRAMMATIC MEDICAMENT TITRATION WITH A MEDICAMENT DELIVERY DEVICE

    公开(公告)号:US20240148971A1

    公开(公告)日:2024-05-09

    申请号:US18386647

    申请日:2023-11-03

    CPC classification number: A61M5/1723 A61M5/14248 A61M2202/0486

    Abstract: Exemplary embodiments may provide an on-body medicament delivery system that provides basal delivery of a medicament to a type 2 diabetes patient and that automatically performs medicament titration for the patient. The medicament delivery system performs medicament titration based on glucose level readings for the patient. These glucose levels may be provided wirelessly from a glucose sensor, such as a continuous glucose monitor, or may be entered manually by the patient into a management device, such as a smartphone running an application that provides a user interface for the patient to enter the glucose level readings. The medicament delivery system adjusts the basal medicament delivery rate/dose based on the glucose level readings for the patient. The adjustments may be performed by a programmatic mechanism, such as by computer programming instructions executing on a processor.

    INTEGRATION OF A MEDICAMENT DELIVERY DEVICE WITH A SMARTWATCH AND A VEHICLE INFOTAINMENT SYSTEM

    公开(公告)号:US20220193337A1

    公开(公告)日:2022-06-23

    申请号:US17554514

    申请日:2021-12-17

    Abstract: The exemplary embodiments may provide a smartwatch or a vehicle infotainment system with management and data inspection capabilities for a medicament delivery system. A user may view medicament delivery history and analyte level history via the smartwatch or auto mobile infotainment system. In addition, a user may calculate a medicament dosage and prompt delivery of the medicament bolus dosage via the smartwatch or vehicle infotainment system. Notifications also may be delivered to the user via the smartwatch and vehicle infotainment system.

    TECHNIQUES FOR RECOMMENDING RESCUE CARBOHYDRATE INGESTION IN AUTOMATIC MEDICATION DELIVERY SYSTEMS

    公开(公告)号:US20230011699A1

    公开(公告)日:2023-01-12

    申请号:US17860609

    申请日:2022-07-08

    Abstract: Provided are techniques, devices and systems that include monitoring a trend of blood glucose measurement values over a series of measurement cycles. A processor may identify a potential excursion outside a range of a target blood glucose measurement value setting of a user based on the monitored trend. In response to the identified potential excursion, an alert may be generated to the user to consume rescue carbohydrates. In addition, the disclosed techniques may include a processor that assesses the factors related to a potential impending hypoglycemic event for a user. Based on a result of the assessment of the factors, the processor may determine whether the user is approaching the potential impending hypoglycemic event for the user. In response to a determination that the user is approaching the potential impending hypoglycemic event for the user, a number of rescue carbohydrates to suggest for consumption by the user may be determined.

    WEARABLE MICRO-DOSING DRUG DELIVERY DEVICE

    公开(公告)号:US20220062536A1

    公开(公告)日:2022-03-03

    申请号:US17412729

    申请日:2021-08-26

    Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.

    WEARABLE MICRO-DOSING DRUG DELIVERY DEVICE

    公开(公告)号:US20250065039A1

    公开(公告)日:2025-02-27

    申请号:US18885257

    申请日:2024-09-13

    Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.

Patent Agency Ranking